SEC Comment Letter 0000000000-24-002637 to Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)

Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)
Date: March 11, 2024 · CIK: 0001501756 · Accession: 0000000000-24-002637

View on Edgar

AI Filing Summary & Sentiment

File numbers found in text: 333-277634

Date

March 11, 2024

Author

Not clearly detected

Form

UPLOAD

Company

Adverum Biotechnologies, Inc. (ADVM) (CIK 0001501756)

Letter

United States securities and exchange commission logo March 11, 2024 Linda Rubinstein Chief Financial Officer Adverum Biotechnologies, Inc. 100 Cardinal Way Redwood City, California 94063 Re:Adverum Biotechnologies, Inc. Registration Statement on Form S-3 Filed March 4, 2024 File No. 333-277634 Dear Linda Rubinstein: Our initial review of your registration statement indicates that it fails in numerous material respects to comply with the requirements of the Securities Act of 1933, the rules and regulations thereunder and the requirements of the form. More specifically, it does not appear that financial statements complying with the updating requirements of Rule 8-08 of Regulation S-X are presented in your registration statement. We will provide more detailed comments relating to your registration statement following our review of a substantive amendment that addresses these deficiencies. Please contact Tamika Sheppard at 202-551-8346 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Kenneth Guernsey

Show Raw Text

United States securities and exchange commission logo
March 11, 2024
Linda Rubinstein
Chief Financial Officer
Adverum Biotechnologies, Inc.
100 Cardinal Way
Redwood City, California 94063
Re:Adverum Biotechnologies, Inc.
Registration Statement on Form S-3
Filed March 4, 2024
File No. 333-277634
Dear Linda Rubinstein:
            Our initial review of your registration statement indicates that it fails in numerous
material respects to comply with the requirements of the Securities Act of 1933, the rules and
regulations thereunder and the requirements of the form. More specifically, it does not appear
that financial statements complying with the updating requirements of Rule 8-08 of Regulation
S-X are presented in your registration statement.
            We will provide more detailed comments relating to your registration statement
following our review of a substantive amendment that addresses these deficiencies.
            Please contact Tamika Sheppard at 202-551-8346 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Kenneth Guernsey

SecProbe.io